Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Citi Opens Upside Catalyst Watch on Alnylam Pharmaceuticals (ALNY)
September 20, 2022 5:38 AM EDTCiti analyst David Lebowitz reiterated a Buy rating and $280.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY)
Opens Upside Catalyst WatchFor an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $216.00 yesterday.
... More